Compare Kimberly Clark Corp (KMB) vs Zimmer Biomet Holdings Inc (ZBH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kimberly Clark Corp vs Zimmer Biomet Holdings Inc — how do they compare? Kimberly Clark Corp trades at $108.36 (market cap $35.97B), while Zimmer Biomet Holdings Inc trades at $89.92 (market cap $17.63B). The key difference: Kimberly Clark Corp is far larger — about 2× Zimmer Biomet Holdings Inc's market cap, and Kimberly Clark Corp pays the higher dividend (4.73%). Which is the better fit depends on your goals.
| KMB | ZBH | |
|---|---|---|
Market Cap | $35.97B | $17.63B |
Sector | Consumer Staples | Health |
52-Week High | $136.77 | $107.71 |
52-Week Low | $93.05 | $79.58 |
Enterprise Value | $42.51B | $24.68B |
Dividend Yield | 4.73% | 1.05% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kimberly-Clark (KMB) trades at $108.39, showing minimal daily movement with a 0.04% gain. The stock maintains neutral technical signals despite bullish moving averages, with key support at $107 and resistance at $110. Recent earnings beats and a 12.8% net margin highlight fundamental strength, though revenue declined to $16.45B in 2025. The company's Dividend King status and 4.5% yield attract income investors, supported by innovation initiatives and the Arbex joint venture.
KMB offers stable income appeal with analyst consensus target of $115.33 (6.4% upside), but high payout ratios and competitive pressures pose risks. Near-term catalysts include Q2 2026 results on August 4, 2026, while execution on cost management and volume growth will dictate momentum. The stock suits defensive portfolios seeking dividend reliability amid market uncertainty.
Zimmer Biomet (ZBH) trades at $90.03, down 1.2% on the day, with a bullish technical signal supported by moving averages. The company demonstrates strong fundamentals with consistent earnings beats, including Q1 2026 EPS of $2.09 beating expectations of $1.86. Revenue growth continues with 2025 revenue reaching $8.23B, while maintaining healthy margins including 70.03% gross profit margin. Recent developments include strategic acquisitions and expansion into Asia Pacific markets.
ZBH presents a balanced investment case with analyst consensus price target of $97.67 offering 8.5% upside potential. The stock trades at reasonable valuations (P/E 23.61, P/S 2.14) with improving cash flow trends. Key risks include increasing debt levels (debt-to-asset ratio rising to 32.57% in 2025) and competitive pressures in medical technology. The upcoming Q2 2026 earnings report on August 5, 2026 will be crucial for confirming growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Kimberly Clark Corp
With around half of sales from personal care and another third from tissue products, Kimberly-Clark sits as a leading manufacturer of tissue and hygiene realm. Its brand mix includes Huggies, Pull-Ups, Kotex, Depend, Kleenex, and Cottonelle. The firm also operates K-C Professional, which partners with businesses to provide safety and sanitary products for the workplace. Kimberly-Clark generates just over of half its sales in North America and more than 10% in Europe, with the rest primarily concentrated in Asia and Latin America.
Read more on KMB →About Zimmer Biomet Holdings Inc
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants, as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly 70% of total revenue is derived from sales of large joints, another quarter comes from extremities, trauma, and related surgical products.
Read more on ZBH →
